Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus

Thumbnail Image
Manuscript_8.03.pdf(393.64 KB)
Accepted Version
Appendix.doc(31 KB)
Figure 1 .tif(82.53 KB)
Figure 1
Supplementary table 1.doc(34 KB)
Supplementary Table 1
D'Amico, Ferdinando
Solitano, Virginia
Aletaha, Daniel
Hart, Ailsa
Magro, Fernando
Selmi, Carlo
Ng, Siew C.
Al Awadhi, Sameer
Choy, Ernest
Schulze-Koops, Hendrik
Journal Title
Journal ISSN
Volume Title
Elsevier B.V.
Research Projects
Organizational Units
Journal Issue
Several efforts have been made to improve the available therapeutic armamentarium of patients with immune-mediated inflammatory disorders (IMIDs) leading to the development of biobetters. To date, there is no commonly accepted definition of biobetters. Sixteen physicians with expertise in the field of IMIDs from eleven countries attended a virtual international consensus meeting to provide for the first time a definition of biobetter and to identify unmet needs on this topic. Improvements in clinical outcomes and drug pharmacology were considered crucial for the definition of biobetters, while safety profile and patient acceptability were not. In addition, an appropriate balance between clinical outcomes and costs and a shared decision between physicians and patients should guide the decision to use a biobetter. Clinical studies are required to validate the biobetter definition and to investigate their role in the management of patients with IMIDs.
Immune-mediated inflammatory disorders , Biobetters , Definition , Consensus
D'Amico, F., Solitano, V., Aletaha, D., Hart, A., Magro, F., Selmi, C., Ng, S. C., Al Awadhi, S., Choy, E., Schulze-Koops, H., Bossuyt, P., Olivera, P. A., Kotze, P. G., Ghosh, S., Peyrin-Biroulet, L. and Danese, S. (2021) 'Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus', Autoimmunity Reviews, 20(7), 102849 (7pp). doi: 10.1016/j.autrev.2021.102849
Link to publisher’s version